GretchenAnnGignacMD

PubMed

• Enfortumab-vedotin use for urothelial carcinoma in two patients on hemodialysis.
  Harshit Khosla, Sita Bhatt, Ming-Jin Wang, Gretchen Gignac, Kriti Mittal, Jasmine Patel> ;Journal of Oncology Pharmacy Practice. 2024 Mar 12
• Characterizing Referrals for Prostate Cancer Genetic Services in a Safety-Net Hospital.
  Christine M Gunn, Gretchen Gignac, Brianna Hardy, Kimberly Zayhowski, Magdalena Pankowska, Stephanie Loo, Catharine Wang> ;JCO Oncology Practice. 2023 Oct 1
• Delivering Genetic Testing for Patients with Prostate Cancer: Moving Beyond Provider Knowledge as a Barrier to Care.
  Christine M Gunn, Emma X Li, Gretchen A Gignac, Magdalena Pankowska, Stephanie Loo, Kimberly Zayhowski, Catharine Wang> ;Cancer Control. 2023 Mar 22
• "I'm in My Feelings Now": Examination of Advance Care Planning Video Declarations by People with Advanced Cancer from a Safety Net Hospital.
  Lisa M Quintiliani, Genevra F Murray, Katherine Waite, Kathleen Salerno, Gretchen A Gignac, David Yuh, Angelo Volandes, Michael K Paasche-Orlow> ;Journal of Palliative Medicine. 2023 Jan 1
• 1 citations
  Novel plasma exosome biomarkers for prostate cancer progression in co-morbid metabolic disease.
  Naser Jafari, Andrew Chen, Manohar Kolla, Isabella R Pompa, Yuhan Qiu, Rebecca Yu, Pablo Llevenes, Christina S Ennis, Joakin Mori, Kiana Mahdaviani, Meredith Halpin, G...> ;Advances in Cancer Biology - Metastasis. 2022 Dec 1
• 8 citations
  Novel forms of prostate cancer chemoresistance to successful androgen deprivation therapy demand new approaches: Rationale for targeting BET proteins.
  Joakin O Mori, Jordan S Shafran, Marija Stojanova, Mark H Katz, Gretchen A Gignac, Jonathan J Wisco, Christopher M Heaphy, Gerald V Denis> ;The Prostate. 2022 Jun 1
• 49 citations
  The absolute lymphocyte count can predict the overall survival of patients with non-small cell lung cancer on nivolumab: a clinical study
  Theodoros Karantanos, S. Karanika, Bhavna Seth, Gretchen Gignac> ;Clinical & Translational Oncology. 2019 Feb 1
• 1 citations
  Outcomes for Young Men With Localized Intermediate-Risk Prostate Cancer: An Analysis of the NCDB
  Samantha G. Chua, Muhammad M. Qureshi, Graham H. Boyd, Gretchen Gignac, Ariel E. Hirsch> ;Clinical Genitourinary Cancer. 2018 Jun 1
• 8 citations
  Risk factors involved in treatment delays and differences in treatment type for patients with prostate cancer by risk category in an academic safety net hospital.
  Carolyn K. Kan, Muhammad M. Qureshi, Apar Gupta, Ankit Agarwal, Gretchen Gignac, B. Nicolas Bloch, Nicholas Thoreson, Ariel E. Hirsch> ;Advances in Radiation Oncology. 2017 Dec 13
• 11 citations
  Uncontrolled diabetes predicts poor response to novel antiandrogens.
  Theodoros Karantanos, Styliani Karanika, Gretchen Gignac> ;Endocrine-Related Cancer. 2016 Sep 1
• Cardiometabolic and skeletal risk factors in black men with prostate cancer starting androgen deprivation therapy.
  Orvar Gunnarsson, Shehzad Basaria, Gretchen Gignac> ;Cancers. 2015 Apr 22
• The prevalence of metabolic risk factors in black men with prostate cancer undergoing consideration for androgen-deprivation therapy.
  Gunnarsson O, Basaria S, Gignac G> ;J. Clin. Oncol.. 2011-05-20
• 3 citations
  Anatomic differences after robotic-assisted radical prostatectomy and open prostatectomy: implications for radiation field design
  Ariel E. Hirsch, John J. Cuaron, Milos J. Janicek, Kit Mui, Richard Lee, David S. Wang, Richard K. Babayan, Ann Zumwalt, Gretchen Gignac, Wen Tao, Alexander Ozonoff, A...> ;Practical Radiation Oncology. 2009 Nov 1
• Metastatic prostate cancer at diagnosis: Clinical presentation in the post-PSA era.
  Dickstein RJ, Kreshover JE, Milose JC, Gignac GA> ;J. Clin. Oncol.. 2009-05-20
• Biochemical failure after radiation therapy for prostate cancer: Racial differences.
  Chi D, Hirsch AE, Gignac GA> ;J. Clin. Oncol.. 2009-05-20
• 62 citations
  Phase I Study of Samarium-153 Lexidronam With Docetaxel in Castration-Resistant Metastatic Prostate Cancer
  Michael J. Morris, Neeta Pandit-Taskar, Jorge A. Carrasquillo, Chaitanya R. Divgi, Susan F. Slovin, William Kevin Kelly, Dana E. Rathkopf, Gretchen Gignac, David B. So...> ;Journal of Clinical Oncology. 2009 May 20
• 15 citations
  Assessing outcomes in prostate cancer clinical trials: a twenty-first century tower of Babel.
  Gretchen A. Gignac, Michael J. Morris, Glenn Heller, Lawrence H. Schwartz, Howard I. Scher> ;Cancer. 2008 Sep 1
• 504 citations
  Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer
  Daniel C. Danila, Glenn Heller, Gretchen A. Gignac, Rita Gonzalez-Espinoza, Aseem Anand, Erika Tanaka, Hans Lilja, Lawrence H. Schwartz, Steven M. Larson, Martin Fleis...> ;Clinical Cancer Research. 2007 Dec 1
• 5 citations
  Castration resistant, taxane naïve metastatic prostate cancer: current clinical approaches and future directions.
  Gretchen A. Gignac, Michael J. Morris, Maha Hussain> ;The Journal of Urology. 2007 Sep 1
• Magnetic resonance imaging of the bone marrow (MRBM) as an outcome measure for patients with metastatic prostate cancer.
  Gignac GA, Morris MJ, Schwartz LH, Lis E, Scher HI> ;J. Clin. Oncol.. 2006-06-20
• 1 citations
  Long-term medical care of testicular cancer survivors.
  David J Vaughn, Gretchen A Gignac, Anna T Meadows> ;Annals of Internal Medicine. 2002 Mar 19
• Join now to see all